{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T16:44:15Z","timestamp":1649177055611},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00108-021-01061-6","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T10:05:03Z","timestamp":1624442703000},"page":"372-374","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["66\/m mit chronisch lymphatischer Leuk\u00e4mie und akutem Nierenversagen unter Therapie mit Obinutuzumab und Venetoclax"],"prefix":"10.1007","volume":"62","author":[{"given":"N.","family":"Kutsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2147\/OTT.S103864","volume":"10","author":"N Alakel","year":"2017","unstructured":"Alakel\u00a0N et\u00a0al (2017) Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther 10:597\u2013605","journal-title":"Onco Targets Ther"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2020000120","volume":"1","author":"K Fischer","year":"2020","unstructured":"Fischer K, Al-Sawaf O, Hallek M (2020) Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (1):357\u2013362. https:\/\/doi.org\/10.1182\/hematology.2020000120","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"19","key":"1061_CR3","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard\u00a0SC, Jones\u00a0DP, Pui\u00a0CH (2011) The tumor lysis syndrome. N\u00a0Engl J Med 364(19):1844\u20131854","journal-title":"N Engl J Med"},{"issue":"2","key":"1061_CR4","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","volume":"7","author":"FP Tambaro","year":"2020","unstructured":"Tambaro\u00a0FP, Wierda\u00a0WG (2020) Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL\u20112 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol 7(2):e168\u2013e176","journal-title":"Lancet Haematol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01061-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T12:40:52Z","timestamp":1631536852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01061-6"}},"subtitle":["Vorbereitung auf die Facharztpr\u00fcfung: Fall\u00a054"],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":4,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01061-6","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"5 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Kutsch und K.\u00a0Fischer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}